SN
Senti Biosciences, Inc.
SNTI · NASDAQ
$0.31 -3.13% (-$0.01)
1M -17.99%
Market Cap $9.65M
P/E Ratio -
Div. Yield -
ROE 1,539.97%
Bulios Fair Price
$0.45
45.2% upside
Current Price
$0.31
Undervalued Fair Value Overvalued
According to Bulios Fair Price, SNTI is currently undervalued relative to its market price. How does it work?
Bulios Fair Price is an estimate of a stock's fair value from the Bulios valuation model. It is an input for your own analysis, not investment advice. How does it work?
Piotroski F-Score Weak
2/9Valuation
0 /100
Expensive P/S 254.08x
PEG N/A
P/E N/A
Growth
0 /100
Declining Book val. growth 64.72%
Rev. growth 81.15%
FCF growth N/A
Profitability
0 /100
Weak Op. margin 148,734.00%
Gross margin 4,628.95%
FCF margin 100,134.00%
Quality
0 /100
Poor ROA 149.72%
ROIC 227.67%
Asset turnover 0.00x
Debt
27 /100
High Current ratio 0.83x
Net debt/EBITDA N/A
Debt/Equity N/A
Stability
6 /100
Unstable Profitable years 0
Beta 2.12x
EPS volatility 70.29%
Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more
Ask StockBot about SNTI
Online
Sector
Healthcare
Industry
Biotechnology
CEO
Timothy K. Lu
Employees
39
Headquarters
South San Francisco
Upcoming events
12 NOV
Earnings
Upcoming earnings report